Annie Im
Experienced in Smoldering Multiple Myeloma

Dr. Annie Im

Hematology Oncology
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
On Staff At
Offers Telehealth
18 Years of Experience

Experienced in Smoldering Multiple Myeloma
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Annie Im, MD, is an Associate Professor of Medicine at the University of Pittsburgh School of Medicine, and a hematologist/medical oncologist specializing and conducting research in hematologic malignancies (such as acute leukemia), drug development, stem cell transplantation, and graft-versus-host-disease. In addition, Dr. Im leads the chronic graft-versus-host-disease and stem cell transplant survivorship clinic.

Dr. Im is rated as an Experienced provider by MediFind in the treatment of Smoldering Multiple Myeloma. Her top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Stony Brook University Hospital
Residency
University of Pittsburgh School of Medicine
Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
University of Pittsburgh School of Medicine
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232
Call: 412-695-5772
Other Locations
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232
Call: 412-695-5772

Additional Areas of Focus

Dr. Im has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Drug, Other, Radiation
Study Phase: Phase 1
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Carfilzomib for Treatment of Chronic Graft vs. Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

63 Total Publications

Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Journal: Leukemia & lymphoma
Published: April 28, 2025
View All 63 Publications
Similar Doctors
Nishant Tageja
Distinguished in Smoldering Multiple Myeloma
Dr. Nishant Tageja
Hematology Oncology
Distinguished in Smoldering Multiple Myeloma
Dr. Nishant Tageja
Hematology Oncology

UPMC Hillman Cancer Center

400 Oxford Drive, Suite 102, 
Monroeville, PA 
 (9.2 miles away)
412-856-7110
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishant Tageja, MD, is a medical oncologist and hematologist. Dr. Tageja specializes in the treatment of solid tumors such as breast cancer, lung cancer, and colon cancer as well as treatment of all benign and malignant blood disorders including lymphoma, leukemia, and myeloma. Dr. Tageja is rated as a Distinguished provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Breast Cancer, and Bone Marrow Transplant.

Distinguished in Smoldering Multiple Myeloma
Dr. Anastasios Raptis
Hematology Oncology | Hematology | Oncology
Distinguished in Smoldering Multiple Myeloma
Dr. Anastasios Raptis
Hematology Oncology | Hematology | Oncology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (0.6 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

Anastasios Raptis is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Raptis is rated as a Distinguished provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Smoldering Multiple Myeloma
Dr. Arjun Lakshman
Hematology Oncology | Hematology | Oncology
Advanced in Smoldering Multiple Myeloma
Dr. Arjun Lakshman
Hematology Oncology | Hematology | Oncology

Allegheny Clinic

320 E N Ave, Fl 4, 
Pittsburgh, PA 
 (5.4 miles away)
412-359-6800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arjun Lakshman is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Lakshman is rated as an Advanced provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Monoclonal Gammopathy of Undetermined Significance (MGUS).

VIEW MORE SMOLDERING MULTIPLE MYELOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Im's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Im is
      Distinguished
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Im is
      Distinguished
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Chronic Graft Versus Host Disease (cGvHD)
      Dr. Im is
      Distinguished
      . Learn about Chronic Graft Versus Host Disease (cGvHD).
      See more Chronic Graft Versus Host Disease (cGvHD) experts
    • Graft Versus Host Disease (GvHD)
      Dr. Im is
      Distinguished
      . Learn about Graft Versus Host Disease (GvHD).
      See more Graft Versus Host Disease (GvHD) experts
    • Non-Hodgkin Lymphoma
      Dr. Im is
      Distinguished
      . Learn about Non-Hodgkin Lymphoma.
      See more Non-Hodgkin Lymphoma experts
    • Advanced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Im is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Bone Marrow Aspiration
      Dr. Im is
      Advanced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Bone Marrow Transplant
      Dr. Im is
      Advanced
      . Learn about Bone Marrow Transplant.
      See more Bone Marrow Transplant experts
    • Childhood Acute Myeloid Leukemia
      Dr. Im is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Im is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • Leukemia
      Dr. Im is
      Advanced
      . Learn about Leukemia.
      See more Leukemia experts
    View All 7 Advanced Conditions
    • Experienced
    • Acute Erythroid Leukemia (AEL)
      Dr. Im is
      Experienced
      . Learn about Acute Erythroid Leukemia (AEL).
      See more Acute Erythroid Leukemia (AEL) experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Im is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Im is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Myelomonocytic Leukemia
      Dr. Im is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Acute Promyelocytic Leukemia
      Dr. Im is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    • Agranulocytosis
      Dr. Im is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.